Michael Leisch
Impact in
- Hematology top 10%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
-
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
-
- Acute Myeloid Leukemia Research 6
- Blood groups and transfusion 1
- Genetics 4
- Mesenchymal stem cell research 2
- Myeloproliferative Neoplasms: Diagnosis and Treatment 1
- Chronic Lymphocytic Leukemia Research 1
- Co-authors
- Richard Greil (13 shared papers)Lisa Pleyer (6 shared papers)Nadja Zaborsky (5 shared papers)Alexander Egle (7 shared papers)Angela Risch (2 shared papers)Roland Geisberger (3 shared papers)Thomas Melchardt (6 shared papers)Florian Huemer (2 shared papers)
In The Last Decade
Michael Leisch
17 papers receiving 385 citations
Peers
Comparison fields: 5 of 52
- Hematology 145
- Genetics 46
- Health Informatics 9
- Oncology 60
- Biotechnology 14
Countries citing papers authored by Michael Leisch
This map shows the geographic impact of Michael Leisch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Leisch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Leisch more than expected).
Fields of papers citing papers by Michael Leisch
This network shows the impact of papers produced by Michael Leisch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Leisch. The network helps show where Michael Leisch may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Leisch, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 69 | |
| 2 | 2019 | 55 | |
| 3 | 2018 | 46 | |
| 4 | 2021 | 44 | |
| 5 | 2020 | 43 | |
| 6 | 2018 | 36 | |
| 7 | 2023 | 18 | |
| 8 | 2019 | 15 | |
| 9 | 2021 | 15 | |
| 10 | 2017 | 11 | |
| 11 | 2023 | 10 | |
| 12 | 2017 | 9 | |
| 13 | 2022 | 7 | |
| 14 | 2020 | 6 | |
| 15 | 2016 | 3 | |
| 16 | 2021 | 2 | |
| 17 | 2025 | 1 | |
| 18 | 2022 | 0 | |
| 19 | 2026 | 0 |
About Michael Leisch
Michael Leisch is a scholar working on Hematology, Genetics, Oncology, Cancer Research and Economics and Econometrics, having authored 19 papers that have together received 390 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (6 papers), CAR-T cell therapy research (3 papers), Cancer Immunotherapy and Biomarkers (2 papers), Mesenchymal stem cell research (2 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (1 paper), Epigenetics and DNA Methylation (1 paper), Chronic Lymphocytic Leukemia Research (1 paper) and Blood groups and transfusion (1 paper). The work is most often cited by research in Hematology (145 citations), Genetics (46 citations), Health Informatics (9 citations), Oncology (60 citations) and Biotechnology (14 citations). Michael Leisch has collaborated with scholars based in Austria, Germany and Spain. Frequent co-authors include Richard Greil, Lisa Pleyer, Nadja Zaborsky, Alexander Egle, Angela Risch, Roland Geisberger, Thomas Melchardt, Florian Huemer, Gabriel Rinnerthaler and Clemens Hufnagl. Their work appears in journals such as Cancers, International Journal of Molecular Sciences, Blood, Pharmaceuticals and European Journal Of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.